SCHEMBL4677540

SCHEMBL4677540

COc1ccc(Cc2occc2C(=O)C=C(O)C(=O)O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.43
SAE1 Q9UBE0 1/20 0.39
UBA2 Q9UBT2 1/20 0.39
LTA4H P09960 1/20 0.39
LDHA P00338 1/20 0.38
ALOX5 P09917 4/20 0.38
CTBP2 P56545 1/20 0.38
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
PDE10A Q9Y233 1/20 0.37
ALDH1A1 P00352 4/20 0.37
KDM5A P29375 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
USP2 O75604 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HPGD P15428 2/20 0.36
LMNA P02545 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677537 1.00 TP53 (0.43) TP53SAE1UBA2LTA4HLDHA
SCHEMBL4672759 0.87 TP53 (0.47) TP53CTBP2ALDH1A1MEN1KMT2A
SCHEMBL4672763 0.87 TP53 (0.47) TP53CTBP2ALDH1A1MEN1KMT2A
SCHEMBL4676253 0.84 CYP2C19 (0.40) TP53ALDH1A1USP2MEN1KMT2A
SCHEMBL4676250 0.84 CYP2C19 (0.40) TP53ALDH1A1USP2MEN1KMT2A
SCHEMBL4678689 0.84 KMT2A (0.45) TP53ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4678693 0.84 KMT2A (0.45) TP53ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4675032 0.83 ITGB1 (0.35) TP53ALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4675005 0.83 TP53 (0.35) TP53CTBP2ALDH1A1MEN1KMT2A
SCHEMBL4675011 0.83 TP53 (0.35) TP53CTBP2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 TP53 999/4885SAE1 2206/4885UBA2 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.